Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). (Q38078456)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alex Domling

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Grzegorz Dubin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

6

Lutz Weber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Krzysztof Zak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Aleksandra Pecak

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Barbara Rys

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Tad A Holak

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

4 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Patents

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

425-448

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

The role of ubiquitination in the direct mitochondrial death program of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

p53 in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

MDM2 and MDM4: p53 regulators as targets in anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Acetylation is indispensable for p53 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

p53 ubiquitination: Mdm2 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

p53-Mdm2 loop controlled by a balance of its feedback strength and effective dampening using ATM and delayed feedback.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Reactivation of p53: from peptides to small molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Allele-specific p53 mutant reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

The P53 pathway: what questions remain to be explored?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Inactivation of the p53 pathway in retinoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

The N-terminal domain of p53 is natively unfolded.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

The p53-MDM2/MDMX axis - A chemotype perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

A stapled p53 helix overcomes HDMX-mediated suppression of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

p53-Mdm2 inhibitors: patent review (2009 - 2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Patented small molecule inhibitors of p53-MDM2 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Robust NMR screening for lead compounds using tryptophan-containing proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Exhaustive Fluorine Scanning toward Potent p53-Mdm2 Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.765405

10.1517/13543776.2013.765405

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23374098%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference